|Videos|September 22, 2020

How COVID-19 Impacted Antibiotic Resistance | Dr. Debra Goff

Dr. Debra Goff describes the rush to "Just in Case" prescribing of antibiotics early in the COVID-19 pandemic, when less was known about the clinical course of the disease.

Segment Description: Debra Goff, PharmD, describes the rush to "Just in Case" prescribing of antibiotics early in the COVID-19 pandemic, when less was known about the clinical course of the disease.

COVID-19 Hospital Data Reveal Rush to Antibiotics

Coronavirus disease 2019 (COVID-19) can present with bacterial coinfection, but concerns about antibiotic over-prescription haven’t gone away amid the SARS-CoV-2 pandemic.

Soon after visiting 38 hospitals in Michigan, over half of patients hospitalized with suspected COVID-19 received antibiotics, according to authors of a new study in Clinical Infectious Diseases.

Patients were feared to have a bacterial coinfection alongside COVID-19.

But testing later showed that 96.5% of patients only had the coronavirus, making the antibiotic prescriptions superfluous.

Data were collected between 3/13/2020-6/18/2020.

Out of a total 1705 patients with COVID-19, 56.6% were prescribed early empiric antibacterial therapy. Only 3.5% (59/1705) had a confirmed community-onset bacterial infection.

Across the 38 hospitals, early empiric antibacterial use varied greatly from 27%-84%.

“Over time, COVID-19 test turnaround time (returned ≤1 day in March [54.2%, 461/850] vs. in April [85.2%, 628/737], P<.001) and empiric antibacterial use (ARR: 0.71 [0.63-0.81] April vs. March) decreased,” authors reported.

Despite a low prevalence of confirmed community-onset bacterial coinfection, half of patients received early empiric antibacterial therapy.

Antibiotic prescribing in reaction to the pandemic varied by hospital.

“Reducing COVID-19 test turnaround time and supporting stewardship could improve antibacterial use,” study authors concluded.


Related to this article

Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.
Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.